Kadmon Holdings Inc (KDMN) Shares Up -1.5%
Kadmon Holdings Inc (NASDAQ:KDMN) shares were up 1.5% on Friday . The stock traded as high as $3.97 and last traded at $3.85. Approximately 471,621 shares traded hands during trading, a decline of 38% from the average daily volume of 763,700 shares. The stock had previously closed at $3.91.
KDMN has been the subject of a number of research reports. Zacks Investment Research cut shares of Kadmon Holdings from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of Kadmon Holdings in a research note on Monday, June 26th. Piper Jaffray Companies reissued a “buy” rating and issued a $7.00 price objective on shares of Kadmon Holdings in a research note on Friday, July 14th. Finally, ValuEngine cut shares of Kadmon Holdings from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st. One analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $9.85.
The stock has a 50 day moving average of $3.36 and a 200-day moving average of $3.36. The stock’s market capitalization is $195.46 million.
Kadmon Holdings (NASDAQ:KDMN) last announced its earnings results on Thursday, August 3rd. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.05. The company had revenue of $3.00 million for the quarter, compared to analyst estimates of $3.46 million. The firm’s revenue for the quarter was down 53.1% on a year-over-year basis. During the same period last year, the firm earned ($4.40) earnings per share. Equities research analysts expect that Kadmon Holdings Inc will post ($1.54) earnings per share for the current fiscal year.
In other Kadmon Holdings news, major shareholder Goldentree Asset Management Lp sold 349,661 shares of the company’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $2.60, for a total value of $909,118.60. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last ninety days, insiders acquired 14,707 shares of company stock worth $34,294 and sold 687,073 shares worth $1,863,337.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. bought a new stake in Kadmon Holdings during the 2nd quarter valued at approximately $114,000. KCG Holdings Inc. bought a new stake in Kadmon Holdings during the 1st quarter valued at approximately $124,000. Renaissance Technologies LLC bought a new stake in Kadmon Holdings during the 1st quarter valued at approximately $158,000. Bank of New York Mellon Corp boosted its stake in Kadmon Holdings by 302.3% during the 1st quarter. Bank of New York Mellon Corp now owns 46,304 shares of the company’s stock valued at $167,000 after purchasing an additional 34,794 shares during the period. Finally, Wells Fargo & Company MN boosted its stake in Kadmon Holdings by 84.8% during the 1st quarter. Wells Fargo & Company MN now owns 51,291 shares of the company’s stock valued at $186,000 after purchasing an additional 23,541 shares during the period.
TRADEMARK VIOLATION NOTICE: This article was first reported by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.watchlistnews.com/kadmon-holdings-inc-kdmn-shares-up-1-5/1613554.html.
About Kadmon Holdings
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.